Vendor Intelligence Report: Shanghai Wibson Biotechnology WBS

Published 3 Jul 2026. 23-page investigative report on who is behind Shanghai Wibson Biotechnology WBS: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 23 Finnrick lab tests, WBS records 19 pass / 3 fail classifications, an overall pass rate of 83%. The lab story is usable but narrow: WBS has real product in the record, not just storefront claims, and both tracked lines usually pass. Tirzepatide is the more defensible WBS choice on present data, while Retatrutide is more batch-sensitive after one labeled vial tested near half of its stated amount and lacked a usable batch ID. The ratings also become less forgiving under stricter grading, where fill accuracy, endotoxin behavior, and traceability matter more than simple identity.

The identity record is less settled than the vendor branding suggests. WBS presents as a Shanghai biotechnology manufacturer with a long operating history, but WHOIS, Wayback, and forum-account timing do not support the claimed 16-year footprint. An archived official page carried a placeholder ICP string, the current canonical domain was parked or redirecting during the field run, and a B2B profile classifies the business as a trading company rather than a verified manufacturer.

The sales apparatus is chiefly forum-based. The report maps multiple WBS personas using Gmail addresses and UK-country-code WhatsApp/Telegram numbers, including a sponsor-thread operation with a partially supported US-delivery claim. A later WhatsApp suspension notice says customer order information was lost, which turns the contact network from trivia into an operational-control issue.

Bottom line: WBS is not an automatic avoid for every buyer, but it is a product- and batch-specific vendor. Tirzepatide has the cleaner current WBS signal, with an endotoxin caveat; Retatrutide requires test-before-use discipline, label photos, batch-specific COAs, and refusal of no-batch vials.

Inside the full report:

  • Per-product pass/fail rates, methodology-divergence charts, and Appendix A laboratory tables for Retatrutide and Tirzepatide
  • WHOIS, Wayback, ICP-footer, and parked-domain exhibits for wibson.com.cn
  • Lookchem trading-company profile, Jinshan District address, and manufacturer-status analysis
  • Persona and contact ledger for Jinjier, Aris, Becky, Ella, and Gavin across forum and B2B records
  • Retatrutide underdose, missing-batch-ID, and batch 510002 traceability analysis
  • Tirzepatide endotoxin-screening finding and lot-verification guidance

Risk assessment

  • Retatrutide dosing-accuracy risk — high: Retatrutide: Apr. 28, 2026 20mg vial tested 9.98mg (-50.1%) with no batch ID despite an otherwise mostly passing line.
  • Batch traceability and recall risk — high: Most clearly Retatrutide: severe underdose had no batch ID; field notes also recorded no-label/no-batch containers and repeated batch ID 510002.
  • Corporate and official-channel verification risk — high: Unsupported 16-year/manufacturer/ICP claims, parked or redirecting official domain, trading-company profile, and no authoritative channel or COA verification page found.
  • Tirzepatide endotoxin-screening risk — medium: Tirzepatide: May 11, 2026 endotoxin-only test returned low rather than a clean non-detect; line otherwise stronger at 83.55%.
  • Order-continuity and customer-data risk — medium: Jinjier reported WhatsApp suspension and lost customer/tracking information; sales rely on Gmail and +44 WhatsApp/Telegram personas.